Search results

161 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Social care guidelines Remove Social care guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

Proposed [GID-TA10821] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

Proposed [GID-TA10822] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

Proposed [GID-TA10823] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]

Proposed [GID-TA10824] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

Proposed [GID-TA10737] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]

Proposed [GID-TA10732] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]

Proposed [GID-TA10746] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: 10 August 2022

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active ankylosing spondylitis [ID3848]

Proposed [GID-TA10735] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nitisinone for treating alkaptonuria [ID2691]

Proposed [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: 22 December 2021

Type

Technology appraisal guidance

Status

Proposed
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Proposed [GID-TA10660] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tirzepatide for treating type 2 diabetes ID3938

Proposed [GID-TA10835] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sacituzumab govitecan for treating metastatic or unresectable triple-negative breast cancer after 2 or more therapies ID3942

Proposed [GID-TA10829] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940

Proposed [GID-TA10830] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943

Proposed [GID-TA10831] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941

Proposed [GID-TA10832] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mavorixafor for treating WHIM syndrome ID3946

Proposed [GID-TA10833] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947

Proposed [GID-TA10834] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed